BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30217739)

  • 1. Light-enhanced VEGF
    Weyergang A; Fremstedal AS; Skarpen E; Peng Q; Mohamedali KA; Eng MS; Cheung LH; Rosenblum MG; Waltenberger J; Berg K
    J Control Release; 2018 Oct; 288():161-172. PubMed ID: 30217739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxin.
    Weyergang A; Cheung LH; Rosenblum MG; Mohamedali KA; Peng Q; Waltenberger J; Berg K
    J Control Release; 2014 Apr; 180():1-9. PubMed ID: 24531010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Light-enhanced VEGF
    Longva AS; Berg K; Weyergang A
    Front Immunol; 2023; 14():1278000. PubMed ID: 38173721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
    Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
    Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.
    Berstad MB; Cheung LH; Berg K; Peng Q; Fremstedal AS; Patzke S; Rosenblum MG; Weyergang A
    Oncogene; 2015 Oct; 34(44):5582-92. PubMed ID: 25684137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Photochemical activation of the recombinant HER2-targeted fusion toxin MH3-B1/rGel; Impact of HER2 expression on treatment outcome.
    Bull-Hansen B; Cao Y; Berg K; Skarpen E; Rosenblum MG; Weyergang A
    J Control Release; 2014 May; 182():58-66. PubMed ID: 24637464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
    Mohamedali KA; Poblenz AT; Sikes CR; Navone NM; Thorpe PE; Darnay BG; Rosenblum MG
    Cancer Res; 2006 Nov; 66(22):10919-28. PubMed ID: 17108129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitive angiogenesis imaging of orthotopic bladder tumors in mice using a selective magnetic resonance imaging contrast agent containing VEGF121/rGel.
    Cho EJ; Yang J; Mohamedali KA; Lim EK; Kim EJ; Farhangfar CJ; Suh JS; Haam S; Rosenblum MG; Huh YM
    Invest Radiol; 2011 Jul; 46(7):441-9. PubMed ID: 21512397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.
    Mohamedali KA; Kedar D; Sweeney P; Kamat A; Davis DW; Eve BY; Huang S; Thorpe PE; Dinney CP; Rosenblum MG
    Neoplasia; 2005 Oct; 7(10):912-20. PubMed ID: 16242074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2.
    Mohamedali KA; Ran S; Gomez-Manzano C; Ramdas L; Xu J; Kim S; Cheung LH; Hittelman WN; Zhang W; Waltenberger J; Thorpe PE; Rosenblum MG
    BMC Cancer; 2011 Aug; 11():358. PubMed ID: 21849059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel.
    Selbo PK; Rosenblum MG; Cheung LH; Zhang W; Berg K
    PLoS One; 2009 Aug; 4(8):e6691. PubMed ID: 19690617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photochemical delivery of bleomycin induces T-cell activation of importance for curative effect and systemic anti-tumor immunity.
    Norum OJ; Fremstedal ASV; Weyergang A; Golab J; Berg K
    J Control Release; 2017 Dec; 268():120-127. PubMed ID: 29042319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer.
    Bull-Hansen B; Berstad MB; Berg K; Cao Y; Skarpen E; Fremstedal AS; Rosenblum MG; Peng Q; Weyergang A
    Oncotarget; 2015 May; 6(14):12436-51. PubMed ID: 26002552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel.
    Hsu AR; Cai W; Veeravagu A; Mohamedali KA; Chen K; Kim S; Vogel H; Hou LC; Tse V; Rosenblum MG; Chen X
    J Nucl Med; 2007 Mar; 48(3):445-54. PubMed ID: 17332623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disulfonated tetraphenyl chlorin (TPCS2a), a novel photosensitizer developed for clinical utilization of photochemical internalization.
    Berg K; Nordstrand S; Selbo PK; Tran DT; Angell-Petersen E; Høgset A
    Photochem Photobiol Sci; 2011 Oct; 10(10):1637-51. PubMed ID: 21773635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.
    Veenendaal LM; Jin H; Ran S; Cheung L; Navone N; Marks JW; Waltenberger J; Thorpe P; Rosenblum MG
    Proc Natl Acad Sci U S A; 2002 Jun; 99(12):7866-71. PubMed ID: 12060733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer.
    Bai F; Wang C; Lu Q; Zhao M; Ban FQ; Yu DH; Guan YY; Luan X; Liu YR; Chen HZ; Fang C
    Biomaterials; 2013 Aug; 34(26):6163-74. PubMed ID: 23706689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.
    Parameswaran R; Yu M; Lyu MA; Lim M; Rosenblum MG; Groffen J; Heisterkamp N
    Leukemia; 2012 Aug; 26(8):1786-96. PubMed ID: 22373785
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.